BioMarin Pharmaceutical (BMRN)
(Real Time Quote from BATS)
$85.38 USD
+1.29 (1.53%)
Updated Jul 22, 2024 11:06 AM ET
4-Sell of 5 4
D Value D Growth D Momentum F VGM
Detailed Estimates
EPS Estimates
Exp Earnings Date | 7/29/24 |
---|---|
Current Quarter | 0.56 |
EPS Last Quarter | 0.71 |
Last EPS Surprise | 18.33% |
ABR | 1.64 |
Earnings ESP
|
-13.67% |
---|---|
Current Year | 2.87 |
Next Year | 3.74 |
EPS (TTM) | 2.20 |
P/E (F1) | 29.31 |
Sales Estimates
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | 659.73M | 692.68M | 2.72B | 3.05B |
# of Estimates | 9 | 9 | 10 | 10 |
High Estimate | 675.00M | 713.00M | 2.77B | 3.21B |
Low Estimate | 643.12M | 679.42M | 2.61B | 2.82B |
Year ago Sales | 595.28M | 581.33M | 2.42B | 2.72B |
Year over Year Growth Est. | 10.83% | 19.15% | 12.27% | 12.25% |
Earnings Estimates
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | 0.56 | 0.74 | 2.87 | 3.74 |
# of Estimates | 11 | 9 | 11 | 11 |
Most Recent Consensus | 0.56 | 0.71 | 2.79 | 3.27 |
High Estimate | 0.68 | 0.79 | 3.00 | 4.46 |
Low Estimate | 0.39 | 0.70 | 2.78 | 2.93 |
Year ago EPS | 0.54 | 0.46 | 2.08 | 2.87 |
Year over Year Growth Est. | 3.70% | 60.87% | 37.98% | 30.41% |
Agreement - Estimate Revisions
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Up Last 7 Days | 0 | 0 | 0 | 0 |
Up Last 30 Days | 0 | 0 | 0 | 0 |
Up Last 60 Days | 0 | 0 | 0 | 0 |
Down Last 7 Days | 1 | 0 | 0 | 0 |
Down Last 30 Days | 1 | 0 | 0 | 0 |
Down Last 60 Days | 1 | 0 | 0 | 1 |
Magnitude - Consensus Estimate Trend
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Current | 0.56 | 0.74 | 2.87 | 3.74 |
7 Days Ago | 0.56 | 0.74 | 2.87 | 3.74 |
30 Days Ago | 0.56 | 0.74 | 2.87 | 3.74 |
60 Days Ago | 0.53 | 0.67 | 2.65 | 3.45 |
90 Days Ago | 0.58 | 0.63 | 2.56 | 3.45 |
Upside - Most Accurate Estimate Versus Zacks Consensus
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Most Accurate Estimate | 0.49 | 0.74 | 3.00 | 4.00 |
Zacks Consensus Estimate | 0.56 | 0.74 | 2.87 | 3.74 |
Earnings ESP | -13.67% | 0.00% | 4.56% | 6.90% |
Surprise - Reported Earnings History
Quarter Ending (3/2024) |
Quarter Ending (12/2023) |
Quarter Ending (9/2023) |
Quarter Ending (6/2023) |
Average Surprise | |
---|---|---|---|---|---|
Reported | 0.71 | 0.49 | 0.46 | 0.54 | NA |
Estimate | 0.60 | 0.44 | 0.46 | 0.47 | NA |
Difference | 0.11 | 0.05 | 0.00 | 0.07 | 0.06 |
Surprise | 18.33% | 11.36% | 0.00% | 14.89% | 11.15% |
Quarterly Estimates By Analyst
Zacks Premium Subscription Required Learn more
Annual Estimates By Analyst
Zacks Premium Subscription Required Learn more